EVOlution™: Evotec's powerful and flexible approach to fragment-based drug discovery
Features & Benefits of the EVOlution™ platform include:
- The world's largest high quality fragment library consisting of 40,000 fragments that provide tractable starting points for optimisation
- An integrated and validated set of capabilities encompassing protein production, assay development, access to fragment libraries, fragment screening, structure elucidation and fragment optimisation
- The only platform that integrates two complementary cutting edge fragment screening technologies (Biochemical & NMR systems)
- Optimisation of fragments supported by Evote's comprehensive drug discovery engine validated from target to clinical candidates
- Proven success with more than 10 preclinical candidates provided for our partners
- Scientific Advisory Board (SAB) of eminent scientists to further enhance the technology platform and advise on programme development
Evotec's fragment-based drug discovery (FBDD) offers an innovative approach for identifying novel, small molecule preclinical development candidates. Evotec has implemented a unique and powerful fragment screening platform (EVOlution™) capable of identifying low molecular weight fragments in a biologically relevant environment using ultra sensitive biochemical screening and NMR technologies accessing a library of 40,000 high quality fragments designed and selected by medicinal chemists.
Combining this fragment screening process with subsequent protein-ligand X-ray crystallography, Evotec's EVOlution™ platform can rapidly identify novel small molecule fragment hits for various, often difficult biological targets in a very short period of time. Leveraging its expertise in medicinal chemistry in combination with its fragment optimisation technology, Evotec can then rapidly progress fragment programmes to identify novel lead structures and preclinical development candidates.
Evotec has already validated the EVOlution™ technology against a number of biologically relevant targets including kinases, proteases and protein-protein interactions for therapeutic applications including the central nervous system (CNS), oncology, inflammation, metabolic disease and cardiovascular diseases. In these therapeutic areas Evotec is building a pipeline of programmes for early partnering with Pharmaceutical and Biotechnology companies. Evotec will seek to partner these programmes once they are in lead optimisation.
Evotec is also collaborating with a number of partners using the EVOlution™ technology to identify novel small molecule leads for their targets and plans to enter into more collaborations. Last year Evotec partnered its heat shock protein (Hsp90) programme in oncology with the Italian biotech company DAC, a wholly owned subsidiary of Genextra SPA.
Evotec has established a Scientific Advisory Board (SAB) of eminent scientists to advise on the selection of high quality biological targets for Evotec's pipeline of projects for partnering as well as advising on the development of the programmes and to identify areas to further enhance the technology base.
